Multimodal, scalable and affordable neurocognitive biomarkers

Alzheimer’s disease (AD) biomarkers targeting Aβ, Tau, and Neurodegeneration are creating unprecedented opportunities for its early detection. Adhering to the A/T/N biomarker framework though comes with several challenges, mainly due to high costs. The Joint Program for Neurodegenerative Diseases (JPND) suggested that efforts should also be directed to harmonise promising cognitive tests. The group recommended the Short‐Term Memory Binding (STMB) and Selective Reminding Tests (SRT). To that aim, we need to explore if such memory markers hold differential sensitivity to the AD continuum (Aim1). Whether such deficits are observable in preclinical and prodromal stages of AD regardless of the disease variants (sporadic and familial) is also unclear (Aim2). Moreover, whether combining these cognitive makers with EEG and Eye‐Tracking (ET) would yield neurocognitive biomarkers for AD (Aim3) needs further research.